Drugs / BZ371B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05384379 | Nov 2022 → Mar 2023 | acute respiratory distress syndrome | Biozeus Biopharmaceutical S.A. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BZ371B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05384379 ↗ |
| Action | Activate | “acts as a NO synthase (NOS) enhancer” NCT05384379 ↗ |
| Modality | Peptide | “BZ371B is a small peptide” NCT05384379 ↗ |
| Route | Inhaled | “treated with inhaled BZ371B” NCT05384379 ↗ |